Table 5.
Univariate and multivariate Cox's regression models predicting duration of overall survival in 347 patients with malignancies
| Characteristics¶ (N = 347) | Hazard Ratio | 95% CI | P-value* |
|---|---|---|---|
| Gender and age | |||
| Women (N = 196) | 0.65 | 0.38–1.04 | 0.08 |
| Age ≥ 50 y (N = 212) | 1.21 | 0.77–1.97 | 0.41 |
| Types of cancer | |||
| Breast (N = 74) | 0.64 | 0.39–1.08 | 0.11 |
| Glioblastoma (N = 26) | 3.01 | 1.73–26.7 | 0.006 |
| Colorectal (N = 26) | 1.73 | 0.71–5.93 | 0.19 |
| Lung (N = 23) | 1.16 | 0.40–3.46 | 0.77 |
| Melanoma (N = 23) | 0.55 | 0.25–1.48 | 0.29 |
| Appendix (N = 20) | 0.89 | 0.30–2.67 | 0.84 |
| Types of genetic aberration | |||
| TP53 aberrant (N = 153) | 2 | 1.27–3.31 | 0.004 |
| CDK4/6, CDKN2A/B aberrant (N = 79) | 2.09 | 1.35–4.70 | 0.004 |
| KRAS aberrant (N = 55) | 1.24 | 0.63–2.53 | 0.51 |
| FGFR/FGF aberrant (N = 51) | 0.67 | 0.39–1.26 | 0.24 |
| PIK3CA aberrant (N = 40) | 0.76 | 0.39–1.57 | 0.49 |
| PTEN aberrant (N = 39) | 4.02 | 5.02–31.9 | <0.0001 |
| MYC aberrant (N = 36) | 1.45 | 0.71–3.33 | 0.27 |
| EGFR aberrant (N = 26) | 2.23 | 1.07–9.71 | 0.04 |
| CCND1 aberrant (N = 25) | 0.48 | 0.27–1.21 | 0.15 |
| APC (N = 23) | 1.75 | 0.65–6.69 | 0.22 |
| MCL1 aberrant (N = 22) | 0.49 | 0.25–1.35 | 0.21 |
| NF1 aberrant (N = 22) | 0.74 | 0.28–2.10 | 0.61 |
| ARID1A aberrant (N = 20) | 0.61 | 0.26–1.65 | 0.38 |
| BRCA2 aberrant (N = 20) | 1.09 | 0.38–3.12 | 0.87 |
| Multivariate Cox's regression model (N = 347) | |||
| Women | 0.6 | 0.35–1.02 | 0.06 |
| Glioblastoma | 1.43 | 0.55–3.72 | 0.46 |
| TP53 aberrant | 1.92 | 1.17–3.14 | 0.01 |
| CDK4/6, CDKN2A/B aberrant | 1.67 | 0.92–3.04 | 0.09 |
| PTEN aberrant | 4.83 | 2.63–8.87 | <0.0001 |
| EGFR aberrant | 1.31 | 0.54–3.16 | 0.55 |
¶
Included characteristics with N ≥ 20.
*
P-values (univariate) and hazard ratios with 95% CI are from log-rank test or multivariate Cox's regression model as appropriate. P <0.1 from univariate analysis were included for multivariate analysis.